Eli Lilly makes Mounjaro and Zepbound, medicines based on the active ingredient tirzepatide.
Mounjaro is the brand name for tirzepatide when prescribed for type 2 diabetes, while Zepbound is the brand used for chronic weight management in eligible patients. Both medicines are manufactured and marketed by Eli Lilly and Company, a major pharmaceutical company headquartered in Indianapolis, Indiana.
Tirzepatide acts on two hormone pathways, GIP and GLP-1, which help regulate blood sugar and appetite. The U.S. Food and Drug Administration approved Mounjaro for type 2 diabetes in 2022 and approved Zepbound for chronic weight management in 2023.
A frequent mix-up is confusing tirzepatide with semaglutide. Semaglutide is the active ingredient in Ozempic and Wegovy, which are made by Novo Nordisk. Eli Lilly also has a long history beyond these medicines, including the development and commercialization of insulin products and Prozac.